Excluding Alcon and the Sandoz US oral solids and dermatology business from both 2018 and 2019, group core operating income in 2019 is expected to grow mid-to-high single-digit. Assuming Alcon and the Sandoz US oral solids and dermatology business remain part of Novartis for the full year 2019, group net sales in 2019 are expected to grow low to mid single digit and group core operating income in 2019 is expected to grow mid single digit.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.